Trump drug price plan could nix investment, warns Roche / Photo: SEBASTIEN BOZON - AFP
-
Kospi Falls Below 5,000 as U.S. AI Regulation Fears Trigger Circuit Breaker
-
BYD Drops Rotating Screens in New Models Due to Tech Limits
-
Valsoft's TAG Software Group Enters the Content Operations Market with the Acquisition of Chalco
-
Samsung Leads Global DRAM Market as SK Hynix Gains Share
-
South Korea Proposes Fourth Delay of Cryptocurrency Gains Tax to 2029
-
Kakao Details Spinoff Plan to Monetize AI Through KakaoTalk
-
ASIC Fines Mona Museum Owner's Company for Late Financial Report
-
Business Leaders Condemn Productivity Commission Inquiry for Excluding Tax and Labor Issues
-
Business Leaders Criticize Productivity Commission Inquiry Scope
-
Sheikh Hasina Vows Return to Bangladesh Despite Death Sentence
-
SCANDIC FINANCE ने एलेक्स बोडी को समूह का उपाध्यक्ष नियुक्त किया
-
SCANDIC FINANCE แต่งตั้งอเล็กซ์ โบดี เป็นรองประธานกลุ่มบริษัท
-
SCANDIC FINANCE Grubu, Alex Bodi’yi başkan yardımcılığına atadı
-
Alex Bodi wiceprezesem grupy SCANDIC FINANCE
-
Алекс Боди е назначен за вицепрезидент на групата SCANDIC FINANCE
-
Alex Bodi a SCANDIC FINANCE vállalatcsoport új alelnöke
-
Ο Άλεξ Μπόντι νέος αντιπρόεδρος του ομίλου SCANDIC FINANCE
NYSE - LSE
Trump drug price plan could nix investment, warns Roche
President Donald Trump's plans to dramatically slash drug prices for Americans could make Swiss pharmaceutical giant Roche cancel major investments in the United States, it said Wednesday.
Trump signed an executive order Monday aimed at bringing down the notoriously high prescription drug prices paid by US consumers, news that rattled pharmaceutical companies.
Swiss newspaper NZZ reported Trump's move could lead Roche to reassess plans it announced just last month to invest $50 billion in the United States over five years.
Roche, the world leader in cancer treatments, said in a statement it did not expect Trump's new drugs policy to hurt its business in 2025.
"However, should the proposed EO (executive order) go into effect, Roche's ability to fund the significant investments previously announced in the US will be in question," it said.
Trump has been pushing foreign firms to invest more in the United States, saying the way to avoid his tariff assault on foreign-made goods is to produce them on US soil instead.
Prescription drugs were not targeted in Trump's "Liberation Day" tariff announcements.
Still, Roche appeared to take heed with its April investment announcement, which came just after fellow Swiss rival Novartis said it would increase investment in the United States by $23 billion over five years.
The United States is a key market for Roche, accounting for more than half its pharmaceutical division's revenues.
Roche's US subsidiary Genentech announced a $700-million project Monday to build a new plant in North Carolina, which it says would employ 400 people.
A.Motta--PC
